Improvement in diabetic retinopathy and urine for microalbuminuria with empagliflozin versus teneligliptin. an open label randomized controlled trial

Aim & Objective: To compare the efficacy of empagliflozin versus teneligliptin on diabetic retinopathy and urine for microalbuminuria as add on therapy to metformin monotherapy in patients of uncontrolled T2DM. Material and Methods: The study was randomized, prospective, open label, comparative interventional study conducted at Dr RPGMC Tanda. Out of total 66 patients, 32 patients (Group A) received empagliflozin 25mg/day and 34 (Group B) received teneligliptin 20mg/day in addition to metformin 1000 mg BD. Total 18 patients, 9 in each group had mild to moderate non proliferative diabetic retinopathy (NPDR). Both the groups were evaluated after 6 months. Statistical Analysis: The data is presented as mean+/- SD. Student’s t test was used for data analysis. The p value<0.05 is significant. Results: After 6 months, In group A only 1 patient had mild NPDR, In group B only 3 patients had mild NPDR. There was statistically significant decrease in urine for microalbuminuria in both groups at 6 months, when compared with baseline (both p < 0.001). Conclusion: Non proliferative diabetic retinopathy improved with both the drugs (empagliflozin > teneligliptin) which also proved their potential role in protection from microvascular complications. Both the drugs showed decrease in microalbuminuria by improving diabetic status.